Aytu BioScience Acquires Second Revenue-Generating Urology Product

Company to Begin Marketing Primsol® Solution for Urinary Tract Infections ENGLEWOOD, Colo., Oct. 6, 2015, OTCQB, AYTU, /PRNewswire/  Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, today announced that it has acquired the rights to Primsol® (trimethoprim hydrochloride) oral solution from FSC Laboratories, Inc.  Primsol is the Company s second acquisition of a branded, revenue-generating product in the urology market, adding to its commercial-stage product portfolio, which also includes ProstaScint® for the detection and assessment of prostate cancer. Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections (UTIs).  This differentiated product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients t


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: